{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:57:50Z","timestamp":1790279870574,"version":"4.1.0"},"reference-count":84,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Atopic dermatitis (AD) is a highly heterogeneous inflammatory disease regarding both its pathophysiology and clinical manifestations. However, it is treated according to the \u201cone-size-fits-all\u201d approach, which may restrict response to treatment. Thus, there is an unmet need for the stratification of patients with AD into distinct endotypes and clinical phenotypes based on biomarkers that will contribute to the development of precision medicine in AD. The development of reliable biomarkers that may distinguish which patients with AD are most likely to benefit from specific targeted therapies is a complex procedure and to date none of the identified candidate biomarkers for AD has been validated for use in routine clinical practice. Reliable biomarkers in AD are expected to improve diagnosis, evaluate disease severity, predict the course of disease, the development of comorbidities, or the therapeutic response, resulting in effective and personalized treatment of AD. Among the studied AD potential biomarkers, thymus and activation-regulated chemokine\/C-C motif ligand 17 (TARC\/CCL17) has the greatest evidence-based support for becoming a reliable biomarker in AD correlated with disease severity in both children and adults. In this review, we present the most prominent candidate biomarkers in AD and their suggested use.<\/jats:p>","DOI":"10.3390\/jcm11164639","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T02:42:53Z","timestamp":1660099373000},"page":"4639","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Atopic Dermatitis: Striving for Reliable Biomarkers"],"prefix":"10.3390","volume":"11","author":[{"given":"Styliani","family":"Mastraftsi","sequence":"first","affiliation":[{"name":"1st Department of Dermatology and Venereology, Andreas Sygros Hospital for Skin and Venereal Diseases, Medical School, National and Kapodistrian University of Athens, 16121 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4766-8238","authenticated-orcid":false,"given":"Georgia","family":"Vrioni","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology and Venereology, Andreas Sygros Hospital for Skin and Venereal Diseases, Medical School, National and Kapodistrian University of Athens, 16121 Athens, Greece"},{"name":"Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Bakakis","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology and Venereology, Andreas Sygros Hospital for Skin and Venereal Diseases, Medical School, National and Kapodistrian University of Athens, 16121 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Electra","family":"Nicolaidou","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology and Venereology, Andreas Sygros Hospital for Skin and Venereal Diseases, Medical School, National and Kapodistrian University of Athens, 16121 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Rigopoulos","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology and Venereology, Andreas Sygros Hospital for Skin and Venereal Diseases, Medical School, National and Kapodistrian University of Athens, 16121 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Stratigos","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology and Venereology, Andreas Sygros Hospital for Skin and Venereal Diseases, Medical School, National and Kapodistrian University of Athens, 16121 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7585-1032","authenticated-orcid":false,"given":"Stamatios","family":"Gregoriou","sequence":"additional","affiliation":[{"name":"1st Department of Dermatology and Venereology, Andreas Sygros Hospital for Skin and Venereal Diseases, Medical School, National and Kapodistrian University of Athens, 16121 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ziehfreund, S., Tizek, L., Hangel, N., Fritzsche, M., Weidinger, S., Smith, C., Bryce, P., Greco, D., Bogaard, E., and Flohr, C. (J. Eur. Acad. Dermatol. Venereol., 2022). Requirements and expectations of high-quality biomarkers for atopic dermatitis and psoriasis in 2021\u2014A two-round Delphi survey among international experts, J. Eur. Acad. Dermatol. Venereol., Online ahead of print.","DOI":"10.1111\/jdv.18178"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/exd.13911","article-title":"Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches","volume":"28","author":"Moyle","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaci.2020.04.062","article-title":"Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers","volume":"147","author":"Bakker","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/jcm4050858","article-title":"Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics","volume":"4","author":"Mansouri","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","article-title":"Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?","volume":"139","author":"Bieber","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti\u2013IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jaci.2017.04.015","article-title":"Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials","volume":"140","author":"Han","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Silverberg","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/ACI.0000000000000198","article-title":"Biomarkers for atopic dermatitis: A systematic review and meta-analysis","volume":"15","author":"Thijs","year":"2015","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Biomarkers Definitions Working Group (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 69, 89\u201395.","DOI":"10.1067\/mcp.2001.113989"},{"key":"ref_15","unstructured":"(2022, June 20). WHO International Programme on Chemical Safety Biomarkers in Risk Assessment: Validity and Validation. Available online: http:\/\/www.inchem.org\/documents\/ehc\/ehc\/ehc222.htm."},{"key":"ref_16","unstructured":"FDA-NIH Biomarker Working Group (2022, June 20). BEST (Biomarkers, EndpointS, and Other Tools) Resource, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/."},{"key":"ref_17","unstructured":"EMA (2022, June 20). Glossary: Biomarker, Available online: https:\/\/www.ema.europa.eu\/en\/glossary\/biomarker."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis\u2014a review on behalf of the International Eczema Council","volume":"147","author":"Thyssen","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1177271920974652","DOI":"10.1177\/1177271920974652","article-title":"Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape","volume":"15","author":"Gromova","year":"2020","journal-title":"Biomark. Insights"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jamadermatol.2019.2983","article-title":"Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis","volume":"155","author":"Diaz","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamadermatol.2019.2792","article-title":"Stripping Away Barriers to Find Relevant Skin Biomarkers for Pediatric Atopic Dermatitis","volume":"155","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/all.14490","article-title":"Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin","volume":"76","author":"Pavel","year":"2020","journal-title":"Allergy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jid.2019.03.1160","article-title":"Side-by-Side Comparison of Skin Biopsies and Skin Tape Stripping Highlights Abnormal Stratum Corneum in Atopic Dermatitis","volume":"139","author":"Kim","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1111\/all.13839","article-title":"Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity","volume":"74","author":"Thijs","year":"2019","journal-title":"Allergy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease","volume":"137","author":"Ungar","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/jcm4030479","article-title":"New Developments in Biomarkers for Atopic Dermatitis","volume":"4","author":"Thijs","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jaci.2020.08.041","article-title":"Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities","volume":"147","author":"He","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/cea.12486","article-title":"A panel of biomarkers for disease severity in atopic dermatitis","volume":"45","author":"Thijs","year":"2015","journal-title":"Clin. Exp. Allergy"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jaci.2017.06.046","article-title":"EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients","volume":"140","author":"Thijs","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3389\/fimmu.2018.00630","article-title":"Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis. Front Immunol","volume":"9","author":"Hulshof","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"21514","DOI":"10.1074\/jbc.271.35.21514","article-title":"Molecular Cloning of a Novel T Cell-directed CC Chemokine Expressed in Thymus by Signal Sequence Trap Using Epstein-Barr Virus Vector","volume":"271","author":"Imai","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2222.2006.02430.x","article-title":"Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis","volume":"36","author":"Song","year":"2006","journal-title":"Clin. Exp. Allergy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaci.2003.12.007","article-title":"Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell\u2013attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis","volume":"113","author":"Hijnen","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1399-3038.2011.01225.x","article-title":"Serum TARC and CTACK concentrations in children with atopic dermatitis, allergic asthma, and urticaria","volume":"23","author":"Machura","year":"2012","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/pai.12431","article-title":"Chemokine levels in serum of children with atopic dermatitis with regard to severity and sensitization status","volume":"26","author":"Ahrens","year":"2015","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1399-3038.2009.00851.x","article-title":"Serum measurement of thymus and activation-regulated chemokine\/CCL17 in children with atopic dermatitis: Elevated normal levels in infancy and age-specific analysis in atopic dermatitis","volume":"20","author":"Fujisawa","year":"2009","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2014.07.031","article-title":"Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity","volume":"71","author":"Landheer","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_38","first-page":"240","article-title":"Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments","volume":"32","author":"Yasukochi","year":"2014","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_39","first-page":"1712","article-title":"Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity","volume":"6","author":"Vekaria","year":"2017","journal-title":"F1000Research"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00403-011-1198-9","article-title":"Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis","volume":"304","author":"Kou","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1442-200X.2009.02908.x","article-title":"Changes in serum lactate dehydrogenase activity in children with atopic dermatitis","volume":"52","author":"Morishima","year":"2010","journal-title":"Pediatr. Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2133.1992.tb00677.x","article-title":"Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis","volume":"126","author":"Czech","year":"1992","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000247419","article-title":"Correlation of Eosinophils, Eosinophil Cationic Protein and Soluble lnterleukin-2 Receptor with the Clinical Activity of Atopic Dermatitis","volume":"185","year":"1992","journal-title":"Dermatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bjd.12943","article-title":"Periostin levels correlate with disease severity and chronicity in patients with atopic dermatitis","volume":"171","author":"Kou","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13601-016-0132-9","article-title":"Immunoglobulin free light chains in adult atopic dermatitis patients do not correlate with disease severity","volume":"6","author":"Thijs","year":"2016","journal-title":"Clin. Transl. Allergy"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"73098","DOI":"10.1155\/MI\/2006\/73098","article-title":"The relationship between serum levels of total IgE, IL-18, IL-12, IFN-gamma and disease severity in children with atopic dermatitis","volume":"2006","author":"Aral","year":"2006","journal-title":"Mediat. Inflamm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.iac.2016.08.008","article-title":"Current and Future Biomarkers in Atopic Dermatitis","volume":"37","author":"Thijs","year":"2017","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1172\/JCI58978","article-title":"Periostin promotes chronic allergic inflammation in response to Th2 cytokines","volume":"122","author":"Masuoka","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2332\/allergolint.13-RAI-0685","article-title":"Periostin in skin tissue and skin-related diseases","volume":"63","author":"Yamaguchi","year":"2014","journal-title":"Allergol. Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/pai.12744","article-title":"An association of periostin levels with the severity and chronicity of atopic dermatitis in children","volume":"28","author":"Sung","year":"2017","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jid.2018.03.1517","article-title":"Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype","volume":"138","author":"Simpson","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/all.13239","article-title":"Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis","volume":"73","author":"Furue","year":"2018","journal-title":"Allergy"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jdermsci.2014.06.001","article-title":"Serum thymus and activation-regulated chemokine (TARC) and interleukin-31 levels as biomarkers for monitoring in adult atopic dermatitis","volume":"75","author":"Kyoya","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1399-3038.2011.01241.x","article-title":"IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis","volume":"23","author":"Raap","year":"2012","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","article-title":"Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis","volume":"118","author":"Neis","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","article-title":"Correlation of IL-31 serum levels with severity of atopic dermatitis","volume":"122","author":"Raap","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/jdv.13679","article-title":"TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis","volume":"30","author":"Nygaard","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.aller.2017.10.005","article-title":"Assessment of IL-31 levels and disease severity in children with atopic dermatitis","volume":"46","author":"Ozceker","year":"2018","journal-title":"Allergol. Immunopathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2011.12.989","article-title":"Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency","volume":"129","author":"Kezic","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jaci.2014.08.005","article-title":"Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention","volume":"134","author":"Simpson","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Glatz, M., Jo, J.-H., Kennedy, E.A., Polley, E.C., Segre, J.A., Simpson, E.L., and Kong, H.H. (2018). Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0192443"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/ng.3424","article-title":"Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis","volume":"47","author":"Paternoster","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1398-9995.2010.02540.x","article-title":"Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity","volume":"66","author":"Kezic","year":"2011","journal-title":"Allergy"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jaci.2008.02.014","article-title":"Filaggrin mutations, atopic eczema, hay fever, and asthma in children","volume":"121","author":"Weidinger","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/sj.jid.5700587","article-title":"Null Mutations in the Filaggrin Gene (FLG) Determine Major Susceptibility to Early-Onset Atopic Dermatitis that Persists into Adulthood","volume":"127","author":"Barker","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4168\/aair.2019.11.1.4","article-title":"Mechanisms by Which Atopic Dermatitis Predisposes to Food Allergy and the Atopic March","volume":"11","author":"Tham","year":"2019","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"eaav2685","DOI":"10.1126\/scitranslmed.aav2685","article-title":"The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype","volume":"11","author":"Leung","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1399-3038.2011.01177.x","article-title":"Prediction of atopic dermatitis in 2-yr-old children by cord blood IgE, genetic polymorphisms in cytokine genes, and maternal mentality during pregnancy","volume":"22","author":"Wen","year":"2011","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2222.2010.03634.x","article-title":"Elevated umbilical cord serum TARC\/CCL17 levels predict the development of atopic dermatitis in infancy","volume":"41","author":"Miyahara","year":"2011","journal-title":"Clin. Exp. Allergy"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaci.2015.12.1306","article-title":"Epidermal thymic stromal lymphopoietin predicts the development of atopic dermatitis during infancy","volume":"137","author":"Kim","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.anai.2020.01.022","article-title":"In vivo Raman spectroscopy discriminates between FLG loss-of-function carriers vs. wild-type in day 1-4 neonates","volume":"124","author":"Nico","year":"2020","journal-title":"Ann. Allergy, Asthma Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.alit.2015.09.004","article-title":"Transepidermal water loss measurement during infancy can predict the subsequent development of atopic dermatitis regardless of filaggrin mutations","volume":"65","author":"Horimukai","year":"2015","journal-title":"Allergol. Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/all.14557","article-title":"Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins","volume":"76","author":"Lauffer","year":"2021","journal-title":"Allergy"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/all.12699","article-title":"Exaggerated IDO1 expression and activity in Langerhans cells from patients with atopic dermatitis upon viral stimulation: A potential predictive biomarker for high risk of Eczema herpeticum","volume":"70","author":"Staudacher","year":"2015","journal-title":"Allergy"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1016\/j.jaip.2020.07.015","article-title":"Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures","volume":"8","author":"Glickman","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jaci.2016.07.013","article-title":"Early-onset pediatric atopic dermatitis is T H 2 but also T H 17 polarized in skin","volume":"138","author":"Esaki","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaci.2015.05.049","article-title":"Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2\/TH1 cell imbalance, whereas adults acquire CLA+ TH22\/TC22 cell subsets","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.jaip.2020.02.022","article-title":"Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity","volume":"8","author":"Nomura","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment","volume":"27","author":"Kaufman","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"244ra90","DOI":"10.1126\/scitranslmed.3008946","article-title":"Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema","volume":"6","author":"Quaranta","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/exd.13077","article-title":"A novel molecular disease classifier for psoriasis and eczema","volume":"25","author":"Krause","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jaci.2020.05.048","article-title":"Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis","volume":"147","author":"He","year":"2021","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/16\/4639\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:06:03Z","timestamp":1760141163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/16\/4639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":84,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["jcm11164639"],"URL":"https:\/\/doi.org\/10.3390\/jcm11164639","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]}}}